Search

Search Constraints

You searched for: Author/Creator Simpson, Eric L

Search Results

2. 330 Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years. (25th January 2023)

3. 359 Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab. (25th January 2023)

5. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Issue 10372 (21st January 2023)

6. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Issue 10228 (21st March 2020)

7. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10356 (17th September 2022)

8. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Issue 10246 (25th July 2020)

9. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Issue 10013 (2nd January 2016)

10. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. Issue 11 (27th November 2020)